ArticleFrontiers in psychiatry2025
Effects of comorbid alexithymia on cognitive impairment in chronic schizophrenia: a large-sample study on the Han Chinese population.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of alexithymia and clinical symptom severity in hospitalized Lebanese patients with schizophrenia.Discover mental health · 2026Article
- Relevant Criteria for Improving Quality of Schizophrenia Spectrum Disorders Treatment: A Delphi Study.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alexithymia and cognitive dysfunction are common in patients with schizophrenia. However, only a few studies have investigated the cognitive performance of patients with schizophrenia and comorbid alexithymia. This study aimed to investigate the relationship between alexithymia and neurocognitive impairment in patients with schizophrenia. Methods: A total of 695 patients who met the DSM-IV diagnostic criteria for schizophrenia were included in this cross-sectional study (male/female = 464/231). Demographic and clinical data were collected using self-reported questionnaires. The severity of alexithymia was assessed using the Toronto Alexithymia Scale (TAS-20), cognitive function was assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) tool, and the severity of psychiatric symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS). Results: The prevalence of comorbid alexithymia in patients with chronic schizophrenia was 31.40%, with a male preponderance. Patients with alexithymia had higher PANSS negative symptom subscale scores and PANSS total scores than those without alexithymia ( Conclusion: This study suggests that patients with chronic schizophrenia with alexithymia have poorer cognitive function than those without alexithymia. Some demographic characteristics and alexithymia are risk factors for cognitive dysfunction in patients with chronic schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.